France 2030 supports KÔL’s clinical study in AMD Laboratoires KÔL has received French government funding under France 2030 to support SKY2, a clinical research programme dedicated to AMD. The study is evaluating aganirsen, an antisense oligonucleoti... Press release R&D
Corneal neovascularisation: KÔL reaches two new milestones KÔL reaches two new milestones in its commitment to rare eye diseases. Orphan drug designation (ODD) in Europe for the prevention of corneal graft rejection marks a first major step forward and highli... R&D
KÔL x Kubota: a new partnership for patients with Stargardt disease KÔL is very proud to announce its collaboration with Kubota Vision Inc. through the signing of a supply and licence agreement to facilitate access in France to emixustat, a drug candidate for the trea... Press release R&D